Actinium Pharmaceuticals, Inc. (ATNM)
EBITDA Growth
521.67%
Quarterly · Period ending:
ATNM EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported521.67%period ending
Latest reported521.67%period ending
ATNM Quarterly EBITDA YoY % (53.61% → 521.67%)
Year-over-year change
High-resolution chart · PNG
ATNM ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 521.6662% | |
| 66.3001% | |
| 11.0732% | |
| 56.669% | |
| 40.2186% | |
| -86.1013% | |
| 29.337% | |
| 13.0774% | |
| 25.4341% | |
| 22.1188% | |
| 12.9792% | |
| -41.3163% | |
| -97.3376% | |
| -117.4479% | |
| -33.1894% | |
| -47.1065% | |
| -55.0899% | |
| 4.8599% | |
| -24.6714% | |
| -14.3221% | |
| -7.422% | |
| 5.8834% | |
| -40.3934% | |
| 15.9358% | |
| 8.5726% | |
| 0.3575% | |
| 29.1753% | |
| -5.8376% | |
| -1.6531% | |
| 11.7786% | |
| -22.2051% | |
| 7.4806% | |
| 31.8403% | |
| 18.5356% | |
| 22.154% | |
| -1.6114% | |
| -8.8748% | |
| -77.6181% | |
| -2.2358% | |
| -67.4217% | |
| 11.3215% | |
| -43.2821% | |
| 4.7827% | |
| 35.1971% | |
| -311.354% | |
| 81.6804% | |
| -16.6723% | |
| -327.0154% | |
| 226.5966% | |
| -2,327.543% | |
| 18.8777% | |
| 47.2957% | |
| -124.0624% | |
| -15.439% | |
| -30,908.4868% | |
| -110,764.1975% | |
| -36,853.2877% | |
| -22,133.6194% | |
| -12.6694% | |
| 69.4032% | |
| 19.6125% | |
| 58.8515% | |
| 449.3902% | |
| -255.8244% | |
| -98.0578% | |
| -68.9933% | |
| -22.0393% | |
| -6.5903% | |
| 74.5785% | |
| 60.2885% | |
| -40.3556% | |
| 54.9968% | |
| -192.3944% | |
| -2,131.0345% | |
| 40.032% | |
| 53.6092% |